Objective: A major challenge for obesity treatment is the maintenance of reduced body weight. Diet-induced obese mice are resistant to achieving normoweight once the obesogenic conditions are reversed, in part because lowered circulating leptin leads to a reduction in metabolic rate and a rebound of hyperphagia that defend the previously elevated body weight set point. Because hypothalamic POMC is a central leptin target, we investigated whether changes in circulating leptin modify Pomc expression to maintain normal energy balance in genetically predisposed obese mice. Methods: Mice with reversible Pomc silencing in the arcuate nucleus (ArcPomc À/À ) become morbidly obese eating low-fat chow. We measured body composition, food intake, plasma leptin, and leptin sensitivity in ArcPomc À/À mice weight-matched to littermate controls by calorie restriction, either from weaning or after developing obesity. Pomc was reactivated by tamoxifen-dependent Cre recombinase transgenes. Long acting PASylated leptin was administered to weight-reduced ArcPomc À/À mice to mimic the super-elevated leptin levels of obese mice.
INTRODUCTION
Weight loss in obese humans can be reliably attained by a sufficient reduction in calorie intake below that of calorie expenditure, with or without concomitant increased physical activity. However, significant weight regain over subsequent years is nearly universal [1] . The inability to maintain weight loss has been attributed to multiple factors including reductions in circulating leptin, but regardless of the precise mechanism this phenomenon has prompted vigorous debate over the concept of altered body weight set point and alternatives to dieting for sustained weight loss, including bariatric surgery and an exploration of polypharmaceutical treatment approaches.
The role of leptin in human energy balance and evidence supporting its major function to signal negative energy balance when levels are low has been reviewed comprehensively by Rosenbaum and Leibel [2] . Many clinical studies [3e8], but not all [9] , support the conclusion that weight loss induced by dieting results in reduced circulating leptin associated with decreased satiation and lower than predicted metabolic rate that, at least in part, contribute to the high recidivism rate for weight regain. Although it is well established that leptin treatment is not an effective measure to induce weight loss in patients with common obesity, it may be beneficial in helping to maintain established weight loss following dieting [2] and recent studies suggest that leptin sensitizing agents may be key to employing leptin pharmacotherapy [10] . Diet-induced obesity (DIO) in mice has been employed frequently as a model with high face value for polygenic obesity in humans. DIO C57BL/6J mice switched to low fat chow exhibit significant weight loss but eventually defend a higher body weight and adiposity index than control mice that never were exposed to the high fat diet [11] . This elevated body weight set point may be due to relative hypometabolism, as found in humans, based on indirect calorimetry measurements [12] . Furthermore, DIO mice whose body weight is reduced to that of control mice by calorie restriction regain more weight when subsequently provided ad libitum access to low fat chow than those pair-fed to control mice that had always been fed low fat chow [13] . Another study using DIO C57BL/6J mice, with or without calorie restriction to reduce their body weight below that of sham controls prior to Roux-En-Y gastric bypass (RYGB) surgery, provides evidence for bidirectional defense of body weight set point [14] . Although the precise physiological mechanism was not determined, the final settling points for body weight and adiposity index were strongly correlated with presurgical values of the same parameters in each mouse. The previously obese mice that were calorie restricted prior to RYGB surgery actually regained weight and fat mass to final levels that were almost the same as those of the DIO mice without calorie restriction. Chronic hyperleptinemia, per se, associated with DIO adiposity does not appear to explain elevated body weight set point because the same phenomenon did not occur in mice fed a low fat diet and chronically infused with leptin to mimic the high endogenous leptin levels of DIO mice [15] . A caveat with use of the DIO mouse model to study the mechanisms regulating body weight set point, and in particular the role of altered leptin levels [15] , is the chronic inflammatory state induced in the liver, adipose tissue and hypothalamus by an excess of fatty acids in the diet [13, 16] . Our laboratory has recently developed an alternative genetic model of obesity in mice fed a standard low fat chow that is based on the conditionally reversible silencing of proopiomelanocortin (Pomc) gene expression in the arcuate nucleus of the hypothalamus (ArcPomc À/À ) [17] . POMC regulates energy balance primarily by controlling feeding behavior and energy expenditure [17, 18] . These effects are largely mediated by POMC-derived melanocortin peptides that are agonists for central melanocortin (MC) 3 and/or 4 receptors, see for review [19] . Consequently, ArcPomc-deficiency causes obesity associated with extreme hyperleptinemia by a combination of hyperphagia, reduced locomotor activity and decreased energy expenditure. Central MC3 and/or 4 receptor signaling is involved in mediating the effects of leptin on energy balance [20e25] . The actions of leptin to reduce body weight and food intake [26, 27] are attenuated in a genetic model of Mc4r À/À mice [28, 29] and in a pharmacological model of rats treated with the MC3/4 antagonist SHU9119 [30] , indicating the importance of the melanocortin system in mediating these functions of leptin. Hypothalamic Pomc expression is upregulated by leptin and reduced in leptin-deficient (ob/ob) or leptin receptor-deficient (db/db) mice [31] . Additionally, restoration of ArcPomc in the leptin receptorexpressing sub-population of hypothalamic POMC neurons was sufficient to normalize energy balance in otherwise ArcPomc À/À mice [32] , further supporting an important interaction of ArcPomc and leptin signaling. Moreover, leptin activates POMC neurons to secrete anorexigenic peptides and inhibits NPY/AgRP neurons to attenuate the release of orexigenic signals [33] . We demonstrated previously that genetic restoration of ArcPomc expression at postnatal day 25 prevented excessive weight gain in the obesity-programmed ArcPomc À/À mice [17] . However, ArcPomc reactivation in older and massively obese mice failed to fully reverse the established obesity phenotype and accompanying metabolic disturbances. In the current study, we hypothesized that leptin-and POMC-mediated control of energy homeostasis are reciprocally linked to each other and that reducing the body weight of obese, hyperleptinemic ArcPomc À/À adult mice by calorie restriction prior to reactivation of Pomc expression would restore their body weight set point to that of lean control mice of the same age. Therefore, we measured plasma leptin levels, leptin sensitivity, and body composition in ArcPomc À/À mice at different ages and under prolonged conditions of ad libitum access to chow or calorie restriction. Moreover, we performed a longitudinal study in calorie restricted ArcPomc À/À mice treated with a novel long acting version of leptin using PASylation technology [34, 35] to mimic the hyperleptinemia of obese ArcPomc À/À mice and better understand the association of leptin sensitivity and the central melanocortin system in regulating energy balance. reduce their body weights to match that of their sex-and age-matched controls. Thereafter, the weight-matched mutant mice and their controls received tamoxifen (50 mg/kg, ip) for each of five consecutive days as described previously [17] during which time the mutant mice were maintained on their calorie restricted diet. Following the last tamoxifen injection, all mice had ad libitum access to chow until they were approximately one-year old at the conclusion of the studies.
METHODS

Animal husbandry
General procedures
Intracerebroventricular (icv) cannulae (Plastics One) were placed into the left lateral ventricle and osmotic mini-pumps (Alzet) were implanted subcutaneously (sc) as described previously [37] . Body composition was measured by NMR using a Minispec LF90II instrument (Bruker Optics). Oral glucose tolerance tests were performed as described previously [37] .
Leptin treatment
For acute experiments, recombinant mouse leptin (National Hormone and Peptide Program) was injected either ip (5 mg/kg in PBS, repeated at 8 h intervals for a total of 3 doses) or icv (2 mg in 2 ml PBS, repeated at 8 h intervals for a total of 3 doses) as described previously [37] . For chronic experiments, leptin was administered by osmotic mini-pumps (10 mg/day sc) for 14 days. PASylated leptin [34, 35] (10 mg/kg in PBS)
was administered sc at 72 h intervals starting one week prior to tamoxifen injections and ending 72 h after the last tamoxifen dose.
Leptin and insulin assays
Plasma leptin and insulin levels were measured by ELISAs following the manufacturers' instructions (R&D Systems, MOB00; Crystal Chem, 90080, respectively). PASylated leptin, rather than the standard leptin included in the ELISA kit, was used to construct the standard curve for analyzing plasma leptin levels during PASylated leptin administration. groups involving one dependent variable with repeated measures were made by repeated measures two-way ANOVAs (RMANOVA) followed by Bonferroni's multiple comparisons test. All analyses were performed separately for data from male and female mice using Prism 6.0 (Graph Pad) and P < 0.05 was considered significant.
RESULTS
Increased adiposity and hyperleptinemia in juvenile ArcPomc
We measured body composition weekly from ages 3 to 6-wk in a cohort of 35 weanlings of all three genotypes and both sexes derived from 9 litters of crosses between ArcPomc þ/À heterozygous mice.
Data from the male mice are shown in Figure 1 . ArcPomc þ/þ and ArcPomc þ/À mice were indistinguishable from each other and therefore their data were combined for statistical analysis. Two-way ANOVAs for body weight, fat mass, lean mass, percentage of fat mass relative to body mass, percentage of lean mass relative to body mass, and ratio of lean to fat mass revealed significant main effects of genotype for each dependent variable (F 1,67 ¼ 9.0, P ¼ 0.0038; F 1,67 ¼ 45.4, P < 0.0001; F 1,67 ¼ 1.8, P ¼ 0.1902; F 1,67 ¼ 67.9, P < 0.0001; F 1,67 ¼ 21.6, P < 0.0001; and F 1,67 ¼ 29.0, P < 0.0001, respectively) except lean mass. Post-hoc multiple comparisons tests indicated there were no significant differences between the two genotypes of mice at ages 3 and 4 wk for any of the six measures (Figure 1AeF ), although trends were evident for divergent body mass and fat mass. However, by age 5-wk, all dependent variables were significantly different between genotypes, except for body mass and lean mass. The results from female mice showed similar patterns compared to males for each of the measures (Supplemental Figure 1) . Taken together, these data reveal that the earliest detected metabolic alteration of weanling ArcPomc À/À mice was increased adiposity that was rapidly augmented from age 5-wk onward. In contrast, body weight was only subtly elevated at age 6-wk in ArcPomc À/À mice.
Leptin levels from an independent cohort of 4 to 6-wk old weightmatched females were increased almost 3-fold in ArcPomc À/À compared to their sibling ArcPomc þ/þ mice (5.1 AE 0.7 and 1.8 AE 0.2 ng/ml, respectively, P < 0.005) (Figure 2A ), consistent with their altered body composition at this early age. These results suggest a direct role of hypothalamic POMC in regulating adiposity and, therefore, plasma leptin levels.
3.2. Peripheral and central leptin treatment failed to reduce body weight and food intake in weight-matched ArcPomc À/À mice Next, we measured plasma leptin levels and leptin sensitivity in weight-matched 8-wk old male ArcPomc À/À mice without any history of overweight. Following weaning, ArcPomc À/À mice were fed 75e 80% of the average amount of chow eaten daily by their ArcPomc
littermates to constantly maintain equivalent body weights between the two genotypes. The reduced quantity of food required by ArcPomc À/À mice to achieve weight matching is consistent with their reduced energy expenditure compared to ArcPomc þ/þ controls [17] . At age 8 wk, weight-matched ArcPomc À/À mice exhibited moderate hyperleptinemia with levels almost four-fold higher than their ArcPomc þ/þ controls ( Figure 2B ). Furthermore, after a return to ad libitum chow at age 16 wk, weight-matched ArcPomc À/À mice became hyperphagic and two weeks of chronic exposure to peripheral leptin treatment by sc osmotic mini-pump did not prevent further increases in their body weight ( Figure 2C ) or food intake ( Figure 2D ) in marked contrast to the reductions of both measures in control mice. In a previous study, we reported that leptin administration at a dose of 10 mg/day delivered by sc mini-pump raised circulating leptin levels of wildtype mice to w12 ng/ml [38] . Leptin transport across the bloodebrain barrier is required for its effects to decrease food intake and body weight [39e41]. To address the possibility of decreased leptin transport into the brain of ArcPomc À/À mice, we tested central leptin sensitivity in a separate cohort of 8-wk old weight-matched mice using icv injection of leptin. Like peripheral leptin administration, icv leptin failed to reduce body weight and food intake in both sexes of weight-matched ArcPomc combined littermate ArcPomc þ/þ (n ¼ 4) and ArcPomc þ/À (n ¼ 3) mice at ages 3e6 wk. *P < 0.05, **P < 0.01, ***P < 0.005, and ****P < 0.0001; Sidak's post-hoc multiple comparisons tests. Data shown are the mean AE SEM.
Original article mice ( Figure 3A ,B). These experiments suggest that reduced leptin transport into the brain was not the underlying cause for impaired leptin sensitivity in the ArcPomc À/À mice. In contrast, we previously showed that acute icv administration of the MC3/4R agonist melanotan II potently reduced food intake and bodyweight in ArcPomc À/À mice [37, 42] , indicating that the fidelity of the melanocortin system downstream of the POMC neurons themselves remains intact. previous studies that showed normal hypothalamic Lepr expression despite leptin resistance in mice with diet-induced obesity [43, 44] .
3.4. Reactivation of ArcPomc expression, following weight reduction by calorie restriction, permanently normalizes body weight and food intake in previously obese mice In our previous study, we found that reactivating Pomc expression in obese middle aged ArcPomc À/À mice only partially corrected their weight and metabolic disturbances [17] . To further explore whether this resilience was related to a leptin resistant state, we performed a longitudinal study with repeated physiological measurements ( Figure 4A ). Specifically, we wanted to determine if reducing body weight, adiposity, and leptin levels in parallel by calorie restriction would improve the efficiency of genetic intervention to reverse obesity. Five to 6-month old, obese ArcPomc À/À mice of both sexes, with or without a Cre-ERT transgene, were calorie restricted for 8 wk (males) or 12 wk (females) to reduce their body weights to the levels of their littermate ArcPomc
controls before reactivating ArcPomc expression by tamoxifen administration ( Figure 4B ). All mice were provided ad libitum chow access following tamoxifen treatment. We found that body weight and food intake were permanently normalized in compound ArcPomc À/À ;Cre-ERT mice due to ArcPomc reactivation in the hypothalamus, while ArcPomc À/À mice without a Cre-ERT transgene rapidly regained weight and exhibited hyperphagia when they were provided ad libitum access to chow after tamoxifen treatment. (Figure 4C,D) . obese, ii) weight-matched by calorie restriction, and iii) following ArcPomc rescue ( Figure 4A ). Consistent with other mouse models of severe obesity [28, 43, 45, 46] , obese ArcPomc À/À mice had extreme hyperleptinemia ( Figure 5A ), and neither body weight ( Figure 5B ) or food intake ( Figure 5C ) were decreased by acute ip leptin administration. Notably, while the calorie restriction procedure was sufficient to normalize the body weight of ArcPomc À/À mice ( Figure 4B ), it did not completely reverse their hyperleptinemia and the mice remained resistant to the effects of exogenous leptin to lower body weight or food intake ( Figure 5A ). Their moderately elevated leptin levels were similar to those found in ArcPomc À/À mice that were calorie restricted following weaning to maintain normal body weight up to age 8 wk ( Figure 2B ). However, following reactivation of ArcPomc expression in the weight reduced ArcPomc À/À ;Cre-ERT2 mice, plasma leptin levels and leptin sensitivity were restored to normal ( Figure 5A ,B,C).
As shown in our previous study [17] , the increased body weight of ArcPomc À/À mice was principally due to excessive accumulation of fat mass. Here, we found that calorie restriction to reduce body weight to the equivalent of their age-matched controls was insufficient to normalize adiposity in the ArcPomc À/À mice ( Figure 6A ,B), thus explaining their residual moderate hyperleptinemia. Remarkably, several weeks after the final tamoxifen dose to reactivate ArcPomc expression, the same mice had normalized fat and lean mass and a fat/lean mass ratio. In contrast, the non-rescued ArcPomc À/À mice quickly reverted to a higher fat mass and fat/lean mass ratio after being allowed to feed ad libitum.
In addition to normalizing food intake, body weight, body composition, and leptin sensitivity, ArcPomc reactivation in weight-reduced ArcPomc À/À mice corrected their hyperinsulinemia ( Figure 7A ) in contrast to the partial reduction observed previously in identically aged, obese ArcPomc À/À ;CAG-Cre-ERT mice treated with tamoxifen [17] .
Obese, insulin-resistant ArcPomc À/À mice have paradoxically improved, not worsened, glucose tolerance because of their reduced renal threshold for glycosuria relative to their ArcPomc þ/þ littermates [37] . Therefore, ArcPomc-rescue actually caused a deterioration of glucose tolerance along with decreased glycosuria to control levels ( Figure 7B ,C and Supplemental Table 1 ), presumably due to restoration of renal sympathetic nervous system activity.
Long-acting PASylated leptin administration prevents normalization of impaired energy balance
To examine whether the reduction in hyperleptinemia between obese and calorie restricted ArcPomc À/À mice influenced the efficacy of ArcPomc reactivation to restore a normal body weight set point, we performed a second longitudinal experiment using an additional cohort of 5 to 6-month old male mice ( Figure 8A ). One group of calorie restricted ArcPomc À/À ;Pomc-Cre-ERT2 mice was treated with PASylated leptin, a modified form of leptin with extended plasma half-life [34, 35] . The dose was chosen to mimic the extreme hyperleptinemia of obese ArcPomc À/À mice ( Figure 5A ) and indeed the treatment raised plasma leptin levels to 95 AE 1 ng/ml prior to the first tamoxifen injection and 90 AE 6 ng/ml following the last tamoxifen injection. A second group of calorie restricted ArcPomc À/À ;Pomc-Cre-ERT2 mice was treated mice had a rapid decrease in weight over two weeks and then stabilized at a level 60% less than their initial weight, but still significantly higher than age-matched control mice. These two groups replicated our previously published findings [17] using the CAG-Cre-ERT transgenic driver line. PASylated leptin administration, bookending the tamoxifen injections, prevented the normalization of body weight, body composition, and food intake, while each of these parameters was normalized in the saline-and tamoxifen-treated, calorie restricted group to levels indistinguishable from the ArcPomc þ/þ mice (Figure 8BeE) . Moreover, the PASylated leptin treated mice actually regained 30% of their lost weight. Their final body weights, fat mass, plasma leptin levels, and food intake were almost the same as those of the group of non-calorie restricted obese ArcPomc À/À ;Pomc-Cre-ERT2 mice 6 wk following tamoxifen administration ( Figure 8BeE ). Next, we assessed hypothalamic Pomc mRNA levels by qRT-PCR in the five experimental groups, 6 wk after tamoxifen treatment ( Figure 8F ). Pomc expression from the reactivated ArcPomc À/À alleles in the ;Cre-ERT for males (n ¼ 6e10) and females (n ¼ 8e10), Tukey's multiple comparisons tests following separate 1-way ANOVAs for each combination of sex and experimental stage. B) 24-h changes in body weight and C) Absolute 24-h food intake after i.p. leptin treatment at the indicated experimental stages; ****P < 0.0001, *** P < 0.005 for leptin vs. saline treated ArcPomc Original article calorie restricted ArcPomc À/À ;Pomc-Cre-ERT2 mice was not different from that of the control ArcPomc þ/þ mice; whereas it was significantly attenuated in both the obese ArcPomc À/À ;Pomc-Cre-ERT2 group and the calorie restricted PASylated leptin treated group following tamoxifen administration ( Figure 8F ). The relative levels of hypothalamic Pomc mRNA correlated inversely with the measured physiological parameters for each group, suggesting that the former are responsible for the latter. The specificity of Pomc rescue in the hypothalamus of ArcPomc À/À ;Pomc-Cre-ERT2 mice 6 wk following tamoxifen treatment was shown by a lack of change in the minimally detectable levels of Pomc mRNA by qRT-PCR in the hippocampus and brain stem (Supplementary Figure 2) where Pomc expression was 20-fold lower than that in the hypothalamus of ArcPomc þ/þ mice and was not different between genotypes. We have never observed POMC peptide immunoreactivity or Pomc mRNA by in situ hybridization in neuronal soma in non-hypothalamic areas of adult mice despite the fact that Pomc-reporter genes often exhibit expression in the brain stem, hippocampus, and amygdala in addition to the Arc [47e49].
DISCUSSION
In this study, we report a direct reciprocal role of hypothalamic POMC and leptin sensitivity in the defense of body weight and adiposity at a given level. Maximal expression of Pomc requires a sensitive leptin signaling pathway to normalize body weight and fat composition and leptin requires POMC to induce its anorectic activity. We found that normal body weight can be restored in aged obese ArcPomc À/À mice only if ArcPomc expression is reinstated after plasma leptin is first reduced below a threshold level by calorie restriction. This observation explains why normal body weight could not be restored in our previous study [17] after reactivation of ArcPomc in obese 6-month old ArcPomc À/À mice, which have significantly higher plasma leptin levels relative to calorie-restricted weight-matched mice ( Figure 5A ). Therefore, findings from this study support the significance of chronic calorie-restriction [1] and, therefore, relatively lower plasma leptin levels in improving the efficiency of clinical interventions to treat obesity. Our data are also consistent with a recent clinical study that showed significant indirect correlations between cerebrospinal fluid (CSF) levels of POMC and BMI, body fat percentage, CSF leptin, and plasma leptin and insulin [50] . ArcPomc À/À mice, whether obese or weight-matched, with or without a history of obesity, showed no change in food intake and body weight in response to exogenous leptin treatment. These results indicate the necessary role of ArcPomc in mediating the effects of leptin on food intake and body weight. While previous animal studies [43, 45] and clinical observations demonstrate that leptin therapy does not effectively reduce weight in obese subjects [51] , we show that leptin treatment is also ineffective in weight-matched mice that lack Pomc in the hypothalamus. Since weight-matched Mc4r À/À mice do respond to leptin treatment [28] , it is possible that the blunted leptin action observed in weight-matched ArcPomc-deficient mice is due to a lack of MC3R signaling by melanocortin activation [21] . Moreover, a recent study [29] reported that while endogenous leptin sensitivity is intact in À/À mice do not respond to endogenous leptin, indicating a critical function of the melanocortin system in mediating leptin action during obesity. Altogether, our data support previous observations [21,28e30,43,52] that melanocortin signaling integrates leptin-mediated effects on energy balance. Our study extends those observations by identifying Pomc expression in the Arc, but not pituitary or hindbrain, as the primary mediator of the actions of leptin to reduce food intake and body weight because ArcPomc-deficient mice have normal Pomc expression in the pituitary and nucleus tractus solitarius [17, 53] . Chronic hyperleptinemia or increased leptin signaling itself contributes to the attenuated ability of leptin to reduce food intake and body weight [54, 55] ; nevertheless, in this study, hyperleptinemia is attributable to increased fat mass due to ArcPomc-deficiency even in the absence of hyperphagia in calorie-restricted mice, a feature that is analogous to Mc3r À/À mice [21, 56, 57] .
In our previous report [17] , we did not measure plasma leptin levels or leptin sensitivity serially in ArcPomc À/À mice. Moreover, it was unclear if the restoration of normal body weight by early, but not delayed, genetic ArcPomc reactivation was associated with restoration of leptin sensitivity. To clarify the role of hypothalamic POMC in leptin sensitivity, we measured plasma leptin levels, and food intake and body weight response after leptin administration in ArcPomc À/À mice.
Interestingly, we found that both obese and weight-matched ArcPomc À/À mice exhibited hyperleptinemia. However, the weightmatched mice had significantly lower plasma leptin levels compared to the obese mice. This reduction in leptin apparently contributed to the restoration of normal weight after ArcPomc reactivation in the weightmatched but not obese mice. Both obese and weight-matched ArcPomc-deficient mice did not decrease food intake or body weight in response to exogenous leptin. Remarkably, hyperleptinemia and leptin resistance were corrected after restoration of ArcPomc expression in weight-matched ArcPomc reactivatable mice. These data indicate a direct association of ArcPomc levels with the effects of leptin to reduce food intake and body weight. The longitudinal study also explains why our previous rescue of ArcPomc expression in weight-matched ArcPomc À/À ;Cre-ERT mice at age 8 wk [17] permanently maintained their body weight and food intake at normal levels with free access to chow. The prevention of obesity by ArcPomc rescue appears to be linked with relatively lower plasma leptin levels or degree of adiposity compared to massively obese mice at the time of ArcPomc reactivation. This observation suggests a critical threshold of plasma leptin levels during which obesity can be normalized by therapeutic interventions; in contrast, if the leptin levels are higher than the threshold, therapeutic interventions might not completely restore bodyweight as observed by us previously in ArcPomc À/À ;Cre-ERT mice [17] . The increased ratio of fat mass to lean mass with normal body weight in the weight-matched ArcPomc À/À mice is reminiscent of the phenotype of Mc3r À/À mice, which have higher fat mass and hyperleptinemia without hyperphagia or hypometabolism [56, 57] . These data confirm that the central melanocortin system directly regulates adiposity, independently of body weight [58] . Remarkably, plasma leptin levels, leptin sensitivity, adiposity, and the ratio of fat mass to lean mass were all corrected after restoration of ArcPomc expression ( Figures 5 and 6 ) in otherwise ArcPomc-deficient aged mice that had a history of massive obesity. Therefore, our data indicate that energy balance derangements in ArcPomc À/À mice are not attributable to any developmental or compensatory changes that might have occurred due to lifelong hypothalamic Pomc-deficiency because the derangements were completely reversed after a combination of prior weight loss by calorie restriction followed by ArcPomc-rescue in obese adult mice.
To further clarify the role of baseline leptin levels in influencing the efficiency of genetic intervention to reverse obesity, we treated calorie restricted reactivatable ArcPomc À/À mice with PASylated leptin [34] , which was previously shown to reverse obesity in leptin-deficient ob/ ob mice [35] . Remarkably, the long-acting leptin treatment prevented maximal rescue of ArcPomc expression and its associated phenotype. Similarly, maximal rescue of Pomc expression was impaired in obese reactivatable ArcPomc À/À mice that have severe endogenous hyperleptinemia. In strong contrast, calorie restricted reactivatable ArcPomc À/À mice not treated with PASylated leptin exhibited a normal metabolic phenotype and reprogramming of their body weight set point after restoration of ArcPomc expression.
In summary, we have demonstrated that ArcPomc-deficiency increases fat mass and the ratio of fat to lean mass, and it impairs the function of leptin to reduce body weight and food intake independently of body weight. Therefore, rescue of ArcPomc expression in weightmatched ArcPomc À/À mice, whether or not there is a history of previous obesity, reestablishes normal energy homeostasis and body weight set point under ad libitum feeding conditions by correcting the abnormal body composition and restoring leptin sensitivity. In contrast, massive hyperleptinemia induced by PASylated leptin administration prevents this normalization by blocking the complete restoration of ArcPomc expression. Therefore, our study reveals a strong reciprocal association between leptin levels and hypothalamic POMC in the regulation of energy homeostasis that is potentially relevant to explain the high recidivism rate for obesity after dieting that is commonly seen in clinical situations. Moreover, our data suggest that reversal of leptin resistance specifically on hypothalamic POMC neurons is a testable Original article mechanism to explain the clinical findings that high dose leptin therapy is effective at maintaining weight loss after calorie restriction and reduction of endogenous leptin, but not for the primary treatment of obesity [2] . Collectively, our study demonstrates that the interaction between hypothalamic leptin sensitivity and Pomc gene expression regulates body weight set point, a phenomenon that can be applied to control obesity more efficiently than targeting either the leptin or POMC signaling pathways alone. discussed results and edited the manuscript for intellectual content. M.J.L. is the guarantor of this work and, as such, had full access to all the data in the study and takes responsibility for integrity of the data and accuracy of its analysis. , from weeks 9e12 revealed a significant interaction of time and group (F 9,42 ¼ 4.3, P < 0.001). B) Final body weight, C) Food intake, D) Fat mass, E) Plasma leptin levels, and F) Hypothalamic Pomc mRNA levels. N ¼ 4e6, **P < 0.01, ***P < 0.005, and ****P < 0.0001 vs. ArcPomc þ/þ ;Pomc-Cre-ERT mice, Dunnett's multiple comparisons test following 1-way ANOVAs for each measurement. CR, calorie restriction; TAM, tamoxifen; PAS-leptin, PASylated leptin. Data shown are the mean AE SEM.
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